tirzepatide and kidney damage Long-Term Demonstrates Benefits in Patients With CKD, Obesity, HFpEF SURPASS-4: Tirzepatide slows kidney disease

If you have gastrointestinal disorders such as severe gastroparesis or inflammatory bowel disease, this medication might worsen your symptoms

GLP-1 receptors exist throughout the digestive tract, not just in the stomach

The tripeptide in food Glutathione can be obtained from different sources

Proactive monitoring of progress when taking semaglutide is necessary, so dosage adjustments can be made accordingly

Dellon et al.: Further reading in NEJM Evidence: Editorial by Alex Straumann, MD, and Luc Biedermann, MD: Eosinophil in EOE Not Everything That Counts Can Be Counted and Not Everything That Can Be Counted Counts #Gastroenterology #ClinicalTrials To view or add a comment, sign in 2 -1 2 : - Very interesting systematic review and meta-analysis of cohort studies combining SGLT-2 inhibitors and GLP-1 receptor agonists just published in Diabetologia by Julia Colombijn and colleagues